15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

Ghent (Belgium), September 18th, 2018 - The Belgian life sciences venture fund V-Bio Ventures (www.v-bio.ventures) today announces that it joins the “Series B” financing round of Horama (www.horama.fr). Horama is a French biotech company based in Paris and Nantes, which specialises in gene therapy for the treatment of rare genetic diseases in ophthalmology.  Willem Broekaert, Managing Partner at V-Bio Ventures, will be appointed to the Horama Board.